Discontinuation of infliximab therapy after acquisition of low disease activity by infliximab in rheumatoid arthritis study: RRR (remission induction by remicade) study

Not Applicable

• Conditions: rheumatoid arthritis

• Registration Number: JPRN-UMIN000002110
• Lead Sponsor: niversity of Occupational & Environmental Health, Japan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-06-23
• Study Completion: 2010-06-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who met the following criteria are excluded. 1) patients who are already in remission and do not use infliximab 2) control with less than 5mg/day of PSL 3) PSL was increased within 4 weeks before the study 4) patients who are not appropriate to the study by a doctor's judgement

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
After discontinuing infliximab, 1. DAS28 (ESR) remains <3.2 for 1 year, 2. Yearly progression of van der Heijde-modified total Sharp score (TSS) remains <0.5 for 1 year.

Secondary Outcome Measures

Name	Time	Method
After discontinuing infliximab, 1. DAS28 (ESR) remains <3.2 for 2 year, 2. Yearly progression of van der Heijde-modified total Sharp score (TSS) remains <0.5 for 2 year.